One is a peptide your own mitochondria encode. The other is the molecule every cell spends to turn food into effort. Together they cover the engine room: the signal to work harder, and the currency that pays for the work.
MOTS-c was only discovered in 2015, and it broke a rule of biology on arrival. Every other peptide we work with is encoded in the nucleus. MOTS-c is encoded inside mitochondrial DNA, which makes it something genuinely different: a message sent from the engine room to the rest of the body.
What the message says is simple. It activates AMPK, the metabolic master switch that hard training, fasting and calorie restriction all converge on. Flip that switch and muscle starts pulling in glucose, burning fat and behaving like it has just been trained. That is why researchers describe MOTS-c as an exercise mimetic. It speaks the exact language training speaks.
In the animal work, MOTS-c injections improved running performance in young, middle aged and old mice alike, and treatment started very late in life still increased physical capacity. Your body clearly rates this peptide too: hard exercise raises your own MOTS-c in muscle and in blood, and levels fall as you age. So this is not a foreign chemical hijacking your metabolism. It is a performance signal you already run on, and one that age steadily turns down.
The original Cell Metabolism paper showed MOTS-c prevented diet induced obesity and age related insulin resistance in mice, by pushing skeletal muscle to take up and burn glucose. Insulin sensitive muscle is the whole game for body composition. It is the difference between carbs becoming training fuel and carbs becoming waistline, and it is exactly where MOTS-c does its work.
Under metabolic stress, MOTS-c physically moves into the cell nucleus and switches on stress resistance genes. A mitochondrial peptide directly instructing the genome had never been seen before. It puts MOTS-c at the centre of how the body coordinates its defence against ageing, not at the edges.
The MOTS-c evidence is deep on mechanism and consistent across the animal performance work, and the human data is on the body's own MOTS-c responding to exercise. No published randomised trial has dosed it in people yet. The FDA's advisory committee still voted it onto the compounding shortlist in July 2026. We would rather you hear the state of play from us than buy certainty from someone else.
Every calorie you have ever eaten became usable energy through NAD+. It is the coenzyme that carries electrons from your food to the machinery that makes ATP. No NAD+, no energy. Not as a figure of speech, as chemistry.
It has a second job that matters just as much for the long game. NAD+ is the fuel for sirtuins and the DNA repair enzymes, the proteins most tightly tied to how well you age. Levels fall hard with age, and when NAD+ runs low the cell is forced to choose between energy today and repair for tomorrow. That choice, repeated for decades, is a decent description of ageing itself.
NAD+ restoration is one of the few areas of longevity science with a stack of human randomised controlled trials behind it, and the core result is not in dispute: raising NAD+ works, reliably and safely. Six weeks of the precursor NR raised NAD+ levels by around 60 percent in a Nature Communications trial. In a trial published in Science, the precursor NMN raised muscle insulin sensitivity by about 25 percent, measured by the gold standard clamp method. A 60 day dose response trial found blood NAD+ up at every dose and six minute walk distance improved versus placebo. And in people with peripheral artery disease, six months of NR bought a 17.6 metre walking gain over placebo, one of the first hard functional wins in the field.
NAD+ itself barely survives digestion, which is why the oral market sells precursors and lets your cells do the converting. We run NAD+ subcutaneously: the molecule itself, delivered past the gut entirely. Our current batch is independently tested by Janoshik at 529mg against a 500mg label, with endotoxins roughly 60 times under the pharmacopoeial limit. The certificates are public in The Prime Vault.
The throughline of all of it is capacity. More NAD+ means mitochondria that can actually meet demand, in a session, across a training week, and across a cut where energy normally falls through the floor. Clients run it for the steady day long energy first. The insulin sensitivity and repair sides are what it is quietly doing underneath.
The pairing is not complicated. MOTS-c is the work order: train harder, burn fat, pull glucose into muscle. NAD+ is the budget that pays for it. Sending the work order without funding it is how you get fatigue. Funding the budget without the order is how you get potential with nothing asking for it. Signal plus currency covers both.
And both act on the same organelle. Mitochondria sit upstream of everything this page is about: output in the gym, what your body does with carbs, the energy you have at 4pm, and the pace you age at. Most supplements work downstream on symptoms. These two go to the room where the decisions get made.
MOTS-c flips the trained switch. The same master switch exercise flips: glucose into muscle, fat on the fire, at every age in the animal work.
NAD+ pays for the work. The energy currency of every cell, with human trials showing restoration is reliable, safe and functional.
Together they cover the engine room. The signal and the currency: performance, body composition, energy and the long game.
A short list rather than an exhaustive one. Every link goes to the paper itself, not to somebody writing about it. For the full study by study breakdown, see The Evidence.
Prime Concierge. Educational information, not medical advice. MOTS-c is prohibited in tested sport at all times under anti-doping rules, so if you compete under those rules, this one is not for you.